1.Rizzoli R, Bruyere O, Cannata-Andia JB, Devogelaer J-, Lyritis G, Ringe JD, et al. Management of osteoporosis in the elderly. Curr Med Res Opin 2009;25:2373-87

2.Arneson TJ, Melton LJ 3rd, Lewallen DG, O’Fallon WM. Epidemiology of diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965-1984. Clin Orthop Relat Res 1988:188-94.

3.Hedström L, Baigi A, Bergh H. The relation between bone mineral density in the heel and pixel intensity in the mandibular jaw bone among elderly women. Dentomaxillofac Radiol 2010;39:409-13

4.Riggs BL, Melton LJ rd. Involutional osteoporosis. N Engl J Med 1986 26;314:1676-86

5.Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81

6.Taguchi A, Tanimoto K, Suei Y, Otani K, Wada T. Oral signs as indicators of possible osteoporosis in elderly women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:612-6.

7.Von Mühlen D, Visby Lunde A, Barrett-Connor E, Bettencourt R. Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in older Caucasian women: The Rancho Bernardo study. Osteoporos Int 1999;10:79-84.

8.World Health Organization. Diet, Nutrition, and the Prevention of Chronic Diseases. Geneva: World Health Organization; 2003. (WHO Technical Report Series, 916

9.Delmas PD, Meunier PJ. The management of Paget’s disease of bone. N Engl J Med 1997;336:558-66.

10.Brodeur JM, Laurin D, Vallee R, Lachapelle D. Nutrient intake and gastrointestinal disorders related to masticatory performance in the edentulous elderly. J Prosthet Dent 1993;70:468-73

11.Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54.

12.Chao M, Hua Q, Yingfeng Z, Guang W, Shufeng S, Yuzhen D, et al. Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 2013;29:1381-4

13.Ruza I, Mirfakhraee S, Orwoll E, Gruntmanis U. Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: Evidence and opinions. Ther Adv Musculoskelet Dis 2013;5:182-98

14.Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-23

15.. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005;20:977-86.

16.Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003;19:395-414.

17.Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462-6.

18.Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000;119:639-46

19.Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. Hepatology 2005;42:762-71.

20.Jonasson G, Jonasson L, Kiliaridis S. Changes in the radiographic characteristics of the mandibular alveolar process in dentate women with varying bone mineral density: A 5-year prospective study. Bone 2006;38:714-21.

21.Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.

22.Cooper C, Melton LJ III. Magnitude and impact of osteoporosis and fracture. In: Marcuse R, Feldman D, Kelsey J, editors. Osteoporosis. San Diago, CA: Academic Press; 1996. p. 419-34.

23.Din SE, Zahran FM, Dahaba MM. Effect of low energy laser therapy in osteoporosis periodontitis patient. Egypt Dent J 200;46:2.

24.Hutchinson M, O’Ryan F, Chavez V, Lathon PV, Sanchez G, Hatcher DC, et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg 2010;68:2232-40.

25.Jonasson G, Bankvall G, Kiliaridis S. Estimation of skeletal bone mineral density by means of the trabecular pattern of the alveolar bone, its interdental thickness, and the bone mass of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:346-52.

26.Shum I, Leung PC, Kwok A, Corbet EF, Orwoll ES, Phipps KR, et al. Periodontal conditions in elderly men with and without osteoporosis or osteopenia. J Periodontol 2010;81:1396-402.

27.Al-Sadhen R. Detecting postmenopausal osteoporosis by using pixel intensity of digital panoramic image. Master of Dental Science Thesis, University of Connecticut; 2002.

28.Hastar E, Yilmaz HH, Orhan H. Evaluation of mental index, mandibular cortical index and panoramic mandibular index on dental panoramic radiographs in the elderly. Eur J Dent 2011;5:60-7

29.Law AN, Bollen AM, Chen SK. Detecting osteoporosis using dental radiographs: A comparison of four methods. J Am Dent Assoc 1996;127:1734-42.

30.Nakayama Y, Mori M. The relationship between number of nature teeth and oral health behavior in adult Japanese people. J Natl Inst Public Health 2012;61:366-73

31.Jiang G, Matsumoto H, Yamane J, Kuboyama N, Akimoto Y, Fujii A. Prevention of trabecular bone loss in the mandible of ovariectomized rats. J Oral Sci 2004;46:75-85.

32.Roux C. Potential effects of bisphosphonates on bone ultrastructure. Osteoporos Int 2009;20:1093-5.

33.Klemetti E, Kolmakov S, Kröger H. Pantomography in assessment of the osteoporosis risk group. Scand J Dent Res 1994;102:68-72.

34.Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007;28:1139-45